New shingles vaccine shows promise in Head-to-Head trial

NCT ID NCT06581575

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix, and researchers will monitor side effects and immune markers over several months.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SHINGLES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infectious disease herpes zoster prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • DM Clinical Research - Chicago

    Chicago, Illinois, 60652, United States

  • DM Clinical Research - New Jersey

    Jersey City, New Jersey, 07306, United States

  • DM Clinical Research - Sugarland

    Sugar Land, Texas, 77478, United States

  • Delricht Research

    Charleston, South Carolina, 29407, United States

  • Delricht Research

    Prosper, Texas, 75078, United States

  • Long Beach Research Institute

    Long Beach, California, 90805, United States

  • Noble Clinical Research

    Tucson, Arizona, 85704, United States

  • Quality Clinical Research

    Omaha, Nebraska, 68114, United States